Increased vascular density, changes in macrophage polarity toward M1 phenotype and cancer-associated fibroblast phenotype, decreased infiltration of myeloid cells, and increased infiltration of CD3+, CD4+, and CD8+ T cell lymphocytes, along with increased CD8+ T cell lymphocyte activation were demonstrated after treatment with MRTX1133. The gene discussed is CD8A; the disease is cancer.